- Home
- CELC vs DXC Comparison
CELC vs DXC Comparison
Compare CELC & DXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- DXC
- Stock Information
- Founded
- CELC 2011
- DXC 1959
- Country
- CELC United States
- DXC United States
- Employees
- CELC N/A
- DXC N/A
- Industry
- CELC Medical Specialities
- DXC EDP Services
- Sector
- CELC Health Care
- DXC Technology
- Exchange
- CELC Nasdaq
- DXC Nasdaq
- Market Cap
- CELC 3.1B
- DXC 2.6B
- IPO Year
- CELC 2017
- DXC N/A
- Fundamental
- Price
- CELC $74.11
- DXC $13.68
- Analyst Decision
- CELC Strong Buy
- DXC Hold
- Analyst Count
- CELC 5
- DXC 7
- Target Price
- CELC $69.40
- DXC $15.33
- AVG Volume (30 Days)
- CELC 1.4M
- DXC 2.0M
- Earning Date
- CELC 11-12-2025
- DXC 10-30-2025
- Dividend Yield
- CELC N/A
- DXC N/A
- EPS Growth
- CELC N/A
- DXC 1492.90
- EPS
- CELC N/A
- DXC 2.03
- Revenue
- CELC N/A
- DXC $12,714,000,000.00
- Revenue This Year
- CELC N/A
- DXC N/A
- Revenue Next Year
- CELC N/A
- DXC N/A
- P/E Ratio
- CELC N/A
- DXC $6.73
- Revenue Growth
- CELC N/A
- DXC N/A
- 52 Week Low
- CELC $7.58
- DXC $12.24
- 52 Week High
- CELC $83.00
- DXC $24.83
- Technical
- Relative Strength Index (RSI)
- CELC 64.02
- DXC 52.76
- Support Level
- CELC $71.06
- DXC $13.02
- Resistance Level
- CELC $79.97
- DXC $14.14
- Average True Range (ATR)
- CELC 5.13
- DXC 0.47
- MACD
- CELC 0.11
- DXC 0.08
- Stochastic Oscillator
- CELC 53.43
- DXC 55.25
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.